The American Journal of Medicine
Volume 114, Issue 5 , Pages 377-382, 1 April 2003

Lack of improvement in the treatment of hyperlipidemia among patients with type 2 diabetes

  • Philip S Mehler, MD

      Affiliations

    • Denver Health (PM, RE, TM), Denver, Colorado, USA
    • University of Colorado Health Sciences Center (PM, AE, RE, TM, WH, RS), Denver, Colorado, USA
    • Corresponding Author InformationRequests for reprints should be addressed to Philip S. Mehler, MD, c/o Denver Health, 660 Bannock Street, MC1914, Denver, Colorado, USA 80204
  • ,
  • Anne Esler, PhD

      Affiliations

    • University of Colorado Health Sciences Center (PM, AE, RE, TM, WH, RS), Denver, Colorado, USA
    • Colorado Prevention Center (AE, WH, RE, PM, TM), Denver, Colorado, USA
  • ,
  • Raymond O Estacio, MD

      Affiliations

    • Denver Health (PM, RE, TM), Denver, Colorado, USA
    • University of Colorado Health Sciences Center (PM, AE, RE, TM, WH, RS), Denver, Colorado, USA
  • ,
  • Thomas D MacKenzie, MD, MSPH

      Affiliations

    • Denver Health (PM, RE, TM), Denver, Colorado, USA
    • University of Colorado Health Sciences Center (PM, AE, RE, TM, WH, RS), Denver, Colorado, USA
  • ,
  • William R Hiatt, MD

      Affiliations

    • University of Colorado Health Sciences Center (PM, AE, RE, TM, WH, RS), Denver, Colorado, USA
    • Colorado Prevention Center (AE, WH, RE, PM, TM), Denver, Colorado, USA
  • ,
  • Robert W Schrier, MD

      Affiliations

    • University of Colorado Health Sciences Center (PM, AE, RE, TM, WH, RS), Denver, Colorado, USA

Received 5 June 2002; received in revised form 1 October 2002; accepted 28 October 2002.

Abstract 

Purpose

We investigated the adequacy of treatment of hyperlipidemia in patients with type 2 diabetes, and assessed the temporal trends in adherence to published guidelines.

Methods

We performed a post hoc analysis of 501 patients enrolled in the Appropriate Blood Pressure Control in Diabetes trial. All patients had fasting lipid profiles at baseline and during the 5 years (1993 to 1998) of the trial. Achieving the National Cholesterol Education Panel’s goals for hyperlipidemia management was the primary outcome.

Results

The percentage of patients with a low-density lipoprotein (LDL) cholesterol level less than 130 mg/dL was 53% (n = 266) at baseline and 54% (n = 270) at the end of 5 years (P = 0.75). Almost 14% (n = 69) of these patients continued to have an LDL cholesterol level greater than 160 mg/dL at the completion of the study. Only 19% (n = 25) of the 133 patients with known coronary artery disease had an LDL cholesterol level less than 100 mg/dL at baseline, and only 16% (n = 21) achieved this level at the completion of the study (P = 0.37).

Conclusion

Although prevention of cardiovascular disease in patients with diabetes is a public health priority, our results suggest that hyperlipidemia is being treated suboptimally.

Keywords:  Diabetes, hyperlipidemia, trends, treatment, goals

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This study was funded by a grant (DK50298) from the National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland, and Bayer, Germany.

PII: S0002-9343(02)01566-8

doi:10.1016/S0002-9343(02)01566-8

The American Journal of Medicine
Volume 114, Issue 5 , Pages 377-382, 1 April 2003